RBC Capital Maintains Outperform on Apotex Health, Raises Price Target to C$46

Benzinga · 21h ago
RBC Capital analyst Douglas Miehm maintains Apotex Health (TSX:APTX) with a Outperform and raises the price target from C$43 to C$46.